All In Biotech

Drug Trial Radar · NCT06600321

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

158

Planned (sponsor's estimate)

Start

Dec 30, 2024

Primary completion

Sep 30, 2027

Study completion Oct 31, 2027

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.

Conditions

  • Advanced Hepatocellular Carcinoma
  • Metastatic Hepatocellular Carcinoma

Interventions

  • ALN-BCATDrug

    Administered by intravenous (IV) infusion

  • PembrolizumabDrug

    Administered by intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Adverse Events (AEs)Time frame: From the time of first dose of study drug administration to 30-37 days after the last dose
  2. Severity of AEsTime frame: From the time of first dose of study drug administration to 30-37 days after the last dose
  3. Dose Escalation: Occurrence of Dose-limiting Toxicities (DLTs)Time frame: From the time of first dose of study drug administration up to 21 days
  4. Dose Expansion: Antitumor Activity as assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)Time frame: Up to 30-37 Days after the last dose

Locations

23 sites in 3 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Phoenix, Arizona · Recruiting

  • Clinical Trial Site

    La Jolla, California · Recruiting

  • Clinical Trial Site

    Los Angeles, California · Recruiting

  • Clinical Trial Site

    Jacksonville, Florida · Recruiting

  • Clinical Trial Site

    Atlanta, Georgia · Recruiting

  • Clinical Trial Site

    Chicago, Illinois · Recruiting

  • Clinical Trial Site

    Ann Arbor, Michigan · Recruiting

  • Clinical Trial Site

    Rochester, Minnesota · Recruiting

  • Clinical Trial Site

    New York, New York · Recruiting

  • Clinical Trial Site

    New York, New York · Completed

  • Clinical Trial Site

    Cleveland, Ohio · Recruiting

  • Clinical Trial Site

    Pittsburgh, Pennsylvania · Recruiting

  • Clinical Trial Site

    Dallas, Texas · Recruiting

  • Clinical Trial Site

    Houston, Texas · Recruiting

  • Clinical Trial Site

    San Antonio, Texas · Recruiting

  • Clinical Trial Site

    Richmond, Virginia · Recruiting

  • Clinical Trial Site

    Milan, Italy · Recruiting

  • Clinical Trial Site

    Rozzano, Italy · Recruiting

  • Clinical Trial Site

    Verona, Italy · Recruiting

  • Clinical Trial Site

    Busan, South Korea · Recruiting

  • Clinical Trial Site

    Seongnam, South Korea · Recruiting

  • Clinical Trial Site

    Seongnam, South Korea · Recruiting

  • Clinical Trial Site

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.